Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barusiban in oocyte donors to reduce uterine contractions on day of embryo transfer
2009-012323-29Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in There is no specific canonical disease named "uterine contraction disorder." comparing Barusiban with Placebo (2 arms). Primary endpoint: Frequency of uterine contractions at 30 minutes after start of dosing. Started Oct 2009; status: completed.
02
Drugs
barusiban
03
Conditions
There is no specific canonical disease named "uterine contraction disorder."
Beyond the preview
Go deeper on 2009-012323-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012323-29.